NASDAQ:BDSX Biodesix (BDSX) Stock Forecast, Price & News $1.49 -0.05 (-3.25%) (As of 09/28/2023 ET) Add Compare Share Share Today's Range$1.47▼$1.5250-Day Range$1.04▼$1.7452-Week Range$0.96▼$2.53Volume15,568 shsAverage Volume85,178 shsMarket Capitalization$117.13 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial MediaProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media Biodesix MarketRank™ ForecastAnalyst RatingN/AUpside/DownsideN/AShort InterestHealthy1.97% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.43Based on 2 Articles This WeekInsider TradingAcquiring Shares$203,017 Bought Last QuarterProj. Earnings GrowthGrowingFrom ($0.66) to ($0.51) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.1.58 out of 5 starsMedical Sector892nd out of 969 stocksMedical Laboratories Industry22nd out of 25 stocks N/A Analyst's Opinion Consensus RatingThere is not enough analysis data for Biodesix. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.97% of the float of Biodesix has been sold short.Short Interest Ratio / Days to CoverBiodesix has a short interest ratio ("days to cover") of 3.4, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Biodesix has recently increased by 27.06%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldBiodesix does not currently pay a dividend.Dividend GrowthBiodesix does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BDSX. Previous Next 1.9 News and Social Media Coverage News SentimentBiodesix has a news sentiment score of 0.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.67 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Biodesix this week, compared to 1 article on an average week. Previous Next 3.3 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Biodesix insiders have bought 1,398.17% more of their company's stock than they have sold. Specifically, they have bought $203,017.00 in company stock and sold $13,551.00 in company stock.Percentage Held by Insiders63.80% of the stock of Biodesix is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 21.24% of the stock of Biodesix is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Biodesix are expected to grow in the coming year, from ($0.66) to ($0.51) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Biodesix is -1.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Biodesix is -1.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBiodesix has a P/B Ratio of 5.52. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Biodesix (NASDAQ:BDSX) StockBiodesix, Inc. operates as a data-driven diagnostic solutions company in the United States. The company offers blood-based lung tests, including Nodify XL2 and Nodify CDT tests, together marketed as part of Nodify Lung Nodule Risk Assessment testing strategy, to assess the risk of lung cancer and help in identifying the appropriate treatment pathway and help physicians in reclassifying risk of malignancy in patients with suspicious lung nodules. It also provides GeneStrat ddPCR and VeriStrat tests, which are used in the diagnosis of lung cancer to measure the presence of mutations in the tumor and the state of the patient's immune system to establish the patient's prognosis and help guide treatment decisions; and GeneStrat NGS (NGS) test, a blood-based NGS. In addition, the company, through its partnership with Bio-Rad Laboratories, Inc., provides Bio-Rad SARS-CoV-2 ddPCR, a COVID-19 Test under Biodesix WorkSafe testing program; and Platelia SARS-CoV-2 Total Ab test, an antibody test for detecting a B-cell immune response to SARS-CoV-2 that indicate recent or prior infection. Further, it offers diagnostic and clinical research, as well as clinical trial testing services to biopharmaceutical companies; and discovers, develops, and commercializes companion diagnostics. The company was formerly known as Elston Technologies, Inc. and as changed to Biodesix, Inc. in 2006. Biodesix, Inc. was incorporated in 2005 and is headquartered in Boulder, Colorado.Read More BDSX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BDSX Stock News HeadlinesSeptember 7, 2023 | finance.yahoo.comBiodesix Announces Two Presentations on Lung Cancer Treatment Guidance Tests at the IASLC 2023 World Lung Conference on Lung CancerAugust 26, 2023 | finance.yahoo.comJack Schuler Spends US$217k On Biodesix StockSeptember 28, 2023 | Behind the Markets (Ad)The single greatest medical breakthrough of all time?We are on the cusp of a medical breakthrough. And soon, this single breakthrough could lead to the cure of over 6,000 genetic diseases, including Alzheimer's, heart disease, and even cancer! This reminds me of Amgen, where early investors made as much as 46,751% when they released their revolutionary drug to the market.August 22, 2023 | finance.yahoo.comBiodesix Announces Presentation of New Nodify XL2® Data at AABIP Conference Highlighting Increased Proportion of Biopsies Diagnosing CancerAugust 9, 2023 | finance.yahoo.comBiodesix, Inc. (NASDAQ:BDSX) Q2 2023 Earnings Call TranscriptAugust 1, 2023 | finance.yahoo.comBiodesix to Participate in the Canaccord Genuity 43rd Annual Growth ConferenceJuly 26, 2023 | finance.yahoo.comBiodesix (NASDAQ:BDSX) investors are sitting on a loss of 49% if they invested a year agoJuly 24, 2023 | finance.yahoo.comBiodesix to Report Second Quarter 2023 Financial Results on August 7, 2023September 28, 2023 | Chaikin Analytics (Ad)This Stock Could Go Up 66% or More.Marc Chaikin built the system that isolated NVDA before it became the best-performing stock of 2023. Click here to get his latest buy. More here.July 12, 2023 | finance.yahoo.comBiodesix Announces Publication of the ORACLE Clinical Utility Study with the Primary Endpoint Demonstrating that the Nodify XL2® Test Reduced Unnecessary Invasive Procedures on Benign Lung NodulesJuly 6, 2023 | finance.yahoo.comBiodesix Awarded Advanced Diagnostic Laboratory Test Status for its Nodify CDT® Test by the Center for Medicare and Medicaid ServicesJune 27, 2023 | finance.yahoo.comBiodesix Completes Enrollment of INSIGHT Study Assessing Clinical Utility of the VeriStrat® Blood-Based Host Immune ClassifierJune 1, 2023 | finance.yahoo.comBiodesix Announces Three Abstracts to Be Presented at ASCO 2023 Annual MeetingMay 31, 2023 | finance.yahoo.comBiodesix to Participate in William Blair’s 43rd Annual Growth Stock ConferenceMay 28, 2023 | finance.yahoo.comJack Schuler Spends US$65k On Biodesix Stock \May 25, 2023 | finance.yahoo.comBiodesix Announces Four Presentations of Health Economic Data Highlighting Cost Saving Potential of Nodify Lung® TestingMay 18, 2023 | finance.yahoo.comBiodesix Announces New Clinical Utility Evidence for the Nodify XL2® Nodule Risk Assessment Test to Be Presented at ATS 2023 International ConferenceMay 11, 2023 | finance.yahoo.comBiodesix Announces First Quarter 2023 Results and HighlightsMay 11, 2023 | finance.yahoo.comBiodesix, Inc. (BDSX) Reports Q1 Loss, Tops Revenue EstimatesApril 27, 2023 | finance.yahoo.comBiodesix to Report First Quarter 2023 Financial Results on May 11, 2023April 12, 2023 | finance.yahoo.comInsiders of Biodesix, Inc. (NASDAQ:BDSX) must be frustrated after market cap dropped US$16m since recent purchasesMarch 15, 2023 | finance.yahoo.comBullish Biodesix, Inc. (NASDAQ:BDSX) insiders filled their treasuries with US$34m worth of stock over last yearMarch 8, 2023 | finance.yahoo.comBiodesix, Inc. (NASDAQ:BDSX) Q4 2022 Earnings Call TranscriptMarch 6, 2023 | finance.yahoo.comBiodesix Announces Fourth Quarter and Fiscal Year End 2022 Results and HighlightsMarch 6, 2023 | finance.yahoo.comBiodesix, Inc. (BDSX) Reports Q4 Loss, Misses Revenue EstimatesFebruary 21, 2023 | finance.yahoo.comBiodesix to Report Fourth Quarter and Full Year 2022 Financial Results on March 6, 2023February 16, 2023 | finance.yahoo.comEven after rising 15% this past week, Biodesix (NASDAQ:BDSX) shareholders are still down 39% over the past yearSee More Headlines Receive BDSX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biodesix and its competitors with MarketBeat's FREE daily newsletter. Email Address BDSX Company Calendar Last Earnings8/07/2023Today9/28/2023Next Earnings (Estimated)11/02/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Medical laboratories Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:BDSX CUSIPN/A CIK1439725 Webwww.biodesix.com Phone303-417-0500FaxN/AEmployees245Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.10) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-65,450,000.00 Net Margins-158.72% Pretax Margin-158.72% Return on Equity-1,628.23% Return on Assets-79.00% Debt Debt-to-Equity Ratio5.51 Current Ratio0.90 Quick Ratio0.90 Sales & Book Value Annual Sales$38.21 million Price / Sales3.17 Cash FlowN/A Price / Cash FlowN/A Book Value$0.27 per share Price / Book5.70Miscellaneous Outstanding Shares78,610,000Free Float28,458,000Market Cap$121.06 million OptionableNot Optionable Beta1.25 20 Stocks to Sell NowMarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.Get This Free Report Key ExecutivesMr. Scott Hutton (Age 51)Pres, CEO & Director Comp: $632kMs. Robin Harper Cowie (Age 43)CFO, Sec. & Treasurer Comp: $390.87kDr. Heinrich RöderFounder & CTOMr. Christopher VazquezVP, Controller & Chief Accounting OfficerMr. Jeffrey A. BojarVP of Legal and Regulatory AffairsMr. Mark DeBlockVP of SalesMr. Robbie LuntSr. Director of MarketingMs. Molli HalvorsonDirector of HRDr. Gary Anthony Pestano Ph.D. (Age 56)Chief Devel. Officer Ms. Bobbi CoffinChief Growth OfficerMore ExecutivesKey CompetitorsMDxHealthNASDAQ:MDXHGenetronNASDAQ:GTHInvitaeNYSE:NVTAEnzo BiochemNYSE:ENZHH&L AcquisitionNYSE:HHLAView All CompetitorsInsiders & InstitutionsJack W SchulerBought 87,500 shares on 8/23/2023Total: $149,625.00 ($1.71/share)Jack W SchulerBought 32,556 shares on 8/21/2023Total: $53,391.84 ($1.64/share)Legato Capital Management LLCBought 148,905 shares on 8/18/2023Ownership: 0.450%Worth Venture Partners LLCSold 96,701 shares on 8/15/2023Ownership: 1.607%Wells Fargo & Company MNBought 40,242 shares on 8/15/2023Ownership: 1.072%View All Insider TransactionsView All Institutional Transactions BDSX Stock - Frequently Asked Questions Should I buy or sell Biodesix stock right now? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Biodesix in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" BDSX shares. View BDSX analyst ratings or view top-rated stocks. How have BDSX shares performed in 2023? Biodesix's stock was trading at $2.30 at the start of the year. Since then, BDSX stock has decreased by 33.0% and is now trading at $1.54. View the best growth stocks for 2023 here. Are investors shorting Biodesix? Biodesix saw a increase in short interest in the month of September. As of September 15th, there was short interest totaling 229,600 shares, an increase of 27.1% from the August 31st total of 180,700 shares. Based on an average daily trading volume, of 68,400 shares, the short-interest ratio is currently 3.4 days. Currently, 2.0% of the company's shares are short sold. View Biodesix's Short Interest. When is Biodesix's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, November 2nd 2023. View our BDSX earnings forecast. How were Biodesix's earnings last quarter? Biodesix, Inc. (NASDAQ:BDSX) released its earnings results on Monday, August, 7th. The company reported ($0.17) earnings per share for the quarter, beating the consensus estimate of ($0.21) by $0.04. The firm earned $11.87 million during the quarter, compared to analysts' expectations of $11.38 million. Biodesix had a negative trailing twelve-month return on equity of 1,628.23% and a negative net margin of 158.72%. What guidance has Biodesix issued on next quarter's earnings? Biodesix updated its FY 2023 earnings guidance on Monday, August, 7th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $52.00 million-$55.00 million, compared to the consensus revenue estimate of $53.18 million. When did Biodesix IPO? (BDSX) raised $76 million in an initial public offering (IPO) on Wednesday, October 28th 2020. The company issued 4,200,000 shares at a price of $17.00-$19.00 per share. Morgan Stanley and William Blair acted as the underwriters for the IPO and Canaccord Genuity and BTIG were co-managers. What is Biodesix's stock symbol? Biodesix trades on the NASDAQ under the ticker symbol "BDSX." Who are Biodesix's major shareholders? Biodesix's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Worth Venture Partners LLC (1.61%), Wells Fargo & Company MN (1.07%), BlackRock Inc. (0.52%), Geode Capital Management LLC (0.47%), Legato Capital Management LLC (0.45%) and State Street Corp (0.35%). Insiders that own company stock include Charles M Watts, Chris Vazquez, Gary Anthony Pestano, Hany Massarany, Jack W Schuler, John Patience, Kieran O'kane, Matthew Strobeck, Robert William Georgantas III, Robin Harper Cowie, Ryan H Siurek and Scott Hutton. View institutional ownership trends. How do I buy shares of Biodesix? Shares of BDSX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Biodesix's stock price today? One share of BDSX stock can currently be purchased for approximately $1.54. How much money does Biodesix make? Biodesix (NASDAQ:BDSX) has a market capitalization of $121.06 million and generates $38.21 million in revenue each year. The company earns $-65,450,000.00 in net income (profit) each year or ($1.10) on an earnings per share basis. How many employees does Biodesix have? The company employs 245 workers across the globe. How can I contact Biodesix? The official website for the company is www.biodesix.com. The company can be reached via phone at 303-417-0500 or via email at chris.brinzey@westwicke.com. This page (NASDAQ:BDSX) was last updated on 9/28/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biodesix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.